The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema
NCT05003453
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
72
Enrollment
INDUSTRY
Sponsor class
Conditions
Eczema, Atopic
Interventions
DRUG:
1.5% Palmitoylethanolamide (PEA) sold as Levagen+
DRUG:
Placebo Comparator
Sponsor
RDC Clinical Pty Ltd